MX2018015893A - Compuestos anti-cancer. - Google Patents

Compuestos anti-cancer.

Info

Publication number
MX2018015893A
MX2018015893A MX2018015893A MX2018015893A MX2018015893A MX 2018015893 A MX2018015893 A MX 2018015893A MX 2018015893 A MX2018015893 A MX 2018015893A MX 2018015893 A MX2018015893 A MX 2018015893A MX 2018015893 A MX2018015893 A MX 2018015893A
Authority
MX
Mexico
Prior art keywords
parp2
parp1
tubulin
inhibitors
cancer
Prior art date
Application number
MX2018015893A
Other languages
English (en)
Inventor
J Peto Csaba
M Jablons David
Tsang Tsze
Lemjabbar-Alaoui Hassan
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2018015893A publication Critical patent/MX2018015893A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

La invención provee, entre otras cosas, compuestos útiles para tratar enfermedades tales como cáncer, formulaciones farmacéuticas que contienen dichos compuestos, así como combinaciones de éstos compuestos con al menos un agente terapéutico adicional.
MX2018015893A 2016-06-24 2017-06-23 Compuestos anti-cancer. MX2018015893A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662354449P 2016-06-24 2016-06-24
US201662426095P 2016-11-23 2016-11-23
PCT/US2017/039119 WO2017223516A1 (en) 2016-06-24 2017-06-23 Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2018015893A true MX2018015893A (es) 2019-08-01

Family

ID=59297390

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018015893A MX2018015893A (es) 2016-06-24 2017-06-23 Compuestos anti-cancer.
MX2021013641A MX2021013641A (es) 2016-06-24 2018-12-17 Derivados de ftalazina como inhibidores de parp1, parp2 y/o tubulina utiles para el tratamiento del cancer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021013641A MX2021013641A (es) 2016-06-24 2018-12-17 Derivados de ftalazina como inhibidores de parp1, parp2 y/o tubulina utiles para el tratamiento del cancer.

Country Status (16)

Country Link
US (3) US11072600B2 (es)
EP (1) EP3475272B1 (es)
JP (2) JP7033588B2 (es)
KR (1) KR102494294B1 (es)
CN (1) CN109843874B (es)
AU (1) AU2017280334C1 (es)
BR (1) BR112018076821A2 (es)
CA (1) CA3029004A1 (es)
ES (1) ES2964531T3 (es)
IL (1) IL263917B (es)
MX (2) MX2018015893A (es)
PL (1) PL3475272T3 (es)
PT (1) PT3475272T (es)
SG (1) SG11201811393WA (es)
WO (1) WO2017223516A1 (es)
ZA (1) ZA201808562B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016187620A2 (en) 2015-05-21 2016-11-24 The Regents Of The University Of California Anti-cancer compounds
WO2017095950A2 (en) 2015-11-30 2017-06-08 Children's Medical Center Corporation Compounds for treating proliferative diseases
IL263917B (en) * 2016-06-24 2022-07-01 Univ California Pthalazine derivatives as parp1, parp2 and/or tubulin suppressors for use in cancer therapy
US11590130B2 (en) 2018-04-05 2023-02-28 Noviga Research Ab Combinations of a tubulin polymerization inhibitor and a poly (ADP-ribose) polymerase (PARP) inhibitor for use in the treatment of cancer
CN112574122A (zh) * 2019-09-27 2021-03-30 上海天慈国际药业有限公司 一种奥拉帕尼关键中间体的制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3401171A (en) 1966-03-11 1968-09-10 Smithkline Corp 2-amidobenzimidazoles
SU1019810A1 (ru) 1981-07-28 1991-04-07 Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского Метиловый эфир 5(6)-[1-(2Н)-фталазинонил-4]-1Н-бензимидазолил-2-карбаминовой кислоты, обладающий антигельминтной активностью
SU1218649A1 (ru) 1984-09-19 1991-04-30 Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского Способ получени метилового эфира 5(6)-[1(2Н)-фталазинонил-4-]-1Н-бензимидазолил-2-карбаминовой кислоты формулы
AU2720199A (en) 1998-02-03 1999-08-23 Boehringer Ingelheim Pharma Kg Five-membered, benzo-condensed heterocycles used as antithrombotic agents
AU3076700A (en) 1999-01-26 2000-08-18 Ono Pharmaceutical Co. Ltd. 2h-phthalazin-1-one derivatives and drugs comprising these derivatives as the active ingredient
DE19907813A1 (de) 1999-02-24 2000-08-31 Boehringer Ingelheim Pharma Substituierte bicyclische Heterocyclen, deren Herstellung und deren Verwendung als Arzneimittel
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB2384776C (en) 2000-10-30 2006-02-03 Kudos Pharm Ltd Phthalazinone derivatives
AR042956A1 (es) 2003-01-31 2005-07-13 Vertex Pharma Inhibidores de girasa y usos de los mismos
CA2517629C (en) 2003-03-12 2011-07-12 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US7846959B2 (en) 2004-05-07 2010-12-07 Exelixis, Inc. Raf modulators and methods of use
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
CN101291928A (zh) * 2005-10-19 2008-10-22 库多斯药物有限公司 4-杂芳甲基取代的酞嗪酮衍生物
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
US20080280910A1 (en) * 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
WO2009118382A1 (en) * 2008-03-27 2009-10-01 Janssen Pharmaceutica Nv Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as parp and tubulin polymerization inhibitors
EP3502707A1 (en) 2010-01-29 2019-06-26 metanomics GmbH Means and methods for diagnosing heart failure in a subject
CN102372706A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
EP3925962A1 (en) 2011-05-31 2021-12-22 Rakovina Therapeutics Inc. Tricyclic inhibitors of poly(adp-ribose) polymerase
KR101546743B1 (ko) * 2012-01-16 2015-08-24 한국과학기술원 인돌 유도체 화합물, 이를 포함하는 Ａｂｌ 키나제 저해제 조성물 및 이상세포 성장 질환의 예방 및 치료용 약학 조성물
GEP201706691B (en) 2012-12-31 2017-06-26 Cadila Healthcare Ltd Substituted phthalazin-1 (2h)-one derivatives as selecti- ve inhibitors of poly (adp-ribose) polymerase-1
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
IL263917B (en) 2016-06-24 2022-07-01 Univ California Pthalazine derivatives as parp1, parp2 and/or tubulin suppressors for use in cancer therapy

Also Published As

Publication number Publication date
US20190352283A1 (en) 2019-11-21
KR102494294B1 (ko) 2023-01-31
WO2017223516A1 (en) 2017-12-28
ZA201808562B (en) 2023-12-20
US11072600B2 (en) 2021-07-27
KR20190033534A (ko) 2019-03-29
US20220402894A1 (en) 2022-12-22
AU2017280334C1 (en) 2022-10-20
US20190337928A1 (en) 2019-11-07
AU2017280334A1 (en) 2019-01-17
CN109843874B (zh) 2022-05-27
EP3475272A1 (en) 2019-05-01
PT3475272T (pt) 2023-12-15
CA3029004A1 (en) 2017-12-28
US10640493B2 (en) 2020-05-05
BR112018076821A2 (pt) 2019-04-02
IL263917A (en) 2019-02-28
JP7033588B2 (ja) 2022-03-10
SG11201811393WA (en) 2019-01-30
JP2022037004A (ja) 2022-03-08
ES2964531T3 (es) 2024-04-08
MX2021013641A (es) 2022-01-06
CN109843874A (zh) 2019-06-04
AU2017280334B2 (en) 2021-07-29
IL263917B (en) 2022-07-01
EP3475272B1 (en) 2023-09-13
JP2019522681A (ja) 2019-08-15
PL3475272T3 (pl) 2024-04-29

Similar Documents

Publication Publication Date Title
PH12018502710A1 (en) Heterocyclic compounds as immunomodulators
PH12019501443A1 (en) Benzooxazole derivatives as immunomodulators
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
MX2022005290A (es) Compuestos heterociclicos como inmunomoduladores.
PH12020550901A1 (en) Macrocyclic compounds for treating disease
ZA201808562B (en) Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
NZ752526A (en) Pyrrolobenzodiazepine conjugates
PH12016500871A1 (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MX2017013142A (es) Terapia combinada para tratar cáncer.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
MX2015010829A (es) Compuestos terapeuticos y sus usos.
MX2016004114A (es) Derivados de 1,4-dihidrodioxina fusionada como inhibidores del factor de trascripcion de choque termico 1.
PH12020500665A1 (en) Pladienolide derivatives as spliceosome targeting agents for treating cancer
MX2015010619A (es) Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cancer.
WO2019043176A3 (en) HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY
MX2020011826A (es) Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.
PH12020500666A1 (en) Pladienolide compounds and their use